TransDigm Group INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TransDigm Group INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.83B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $7.94B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $6.59B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $5.43B | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $4.80B | Nov 9, 2023 |
| FY2020 | Sep 30, 2020 | $1.17B | Nov 12, 2020 |
| FY2021 | Sep 30, 2019 | $5.22B | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $3.81B | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $3.50B | Nov 19, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $7.94B | Nov 7, 2024 |
| FY2024 | Sep 30, 2023 | $6.59B | Nov 7, 2024 |
| FY2024 | Sep 30, 2022 | $5.43B | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $4.80B | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $5.10B | Nov 10, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $3.81B | Nov 9, 2018 |
| FY2018 | Sep 30, 2017 | $3.50B | Nov 9, 2018 |
| FY2018 | Sep 30, 2016 | $3.17B | Nov 9, 2018 |
| FY2017 | Sep 30, 2015 | $2.71B | Nov 13, 2017 |
| FY2016 | Sep 30, 2014 | $2.37B | Nov 15, 2016 |
| FY2015 | Sep 30, 2013 | $1.92B | Nov 13, 2015 |
| FY2014 | Sep 30, 2012 | $1.70B | Nov 14, 2014 |
| FY2011 | Sep 30, 2011 | $342.95M | Nov 18, 2011 |
| FY2011 | Jul 2, 2011 | $325.21M | Nov 18, 2011 |
| FY2011 | Apr 2, 2011 | $304.31M | Nov 18, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $5.31B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $4.67B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $3.84B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $3.10B | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $2.51B | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $2.65B | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $2.81B | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $2.18B | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $1.98B | Nov 19, 2019 |
| FY2018 | Sep 30, 2016 | $1.73B | Nov 9, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.07B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $1.71B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $1.30B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $866.00M | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $680.00M | Nov 9, 2023 |
| FY2020 | Sep 30, 2020 | $82.00M | Nov 12, 2020 |
| FY2021 | Sep 30, 2019 | $890.00M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $957.00M | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $596.89M | Nov 19, 2019 |
| FY2018 | Sep 30, 2016 | $586.41M | Nov 9, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.17B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $3.53B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $2.92B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $2.22B | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $1.69B | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $1.75B | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $1.93B | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $1.66B | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $1.48B | Nov 19, 2019 |
| FY2018 | Sep 30, 2016 | $1.27B | Nov 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $118.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $107.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $105.00M | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $95.00M | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $106.00M | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $130.90M | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $116.80M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $73.80M | Nov 12, 2020 |
| FY2019 | Mar 31, 2018 | $73.80M | Nov 19, 2019 |
| FY2019 | Sep 30, 2017 | $73.80M | Nov 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $945.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $980.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $780.00M | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $748.00M | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $685.00M | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $727.00M | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $748.00M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $450.00M | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $412.56M | Nov 19, 2019 |
| FY2018 | Sep 30, 2016 | $382.86M | Nov 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.04B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $2.05B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $1.38B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $948.00M | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $913.00M | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $1.21B | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $1.02B | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $1.02B | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $788.73M | Nov 19, 2019 |
| FY2013 | Sep 30, 2013 | $470.21M | Nov 15, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $222.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $165.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $139.00M | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $119.00M | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $105.00M | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $105.00M | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $102.00M | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $73.00M | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $71.01M | Nov 19, 2019 |
| FY2018 | Sep 30, 2016 | $43.98M | Nov 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $22.91B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $25.59B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $19.97B | Nov 12, 2025 |
| FY2023 | Sep 30, 2022 | $18.11B | Nov 9, 2023 |
| FY2022 | Sep 30, 2021 | $19.32B | Nov 10, 2022 |
| FY2021 | Sep 30, 2020 | $18.40B | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $16.26B | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $12.20B | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $9.98B | Nov 9, 2018 |
| FY2017 | Sep 30, 2016 | $10.73B | Nov 13, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $32.59B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $31.87B | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | $21.95B | Nov 7, 2024 |
| FY2023 | Sep 30, 2022 | $21.87B | Nov 9, 2023 |
| FY2022 | Sep 30, 2021 | $22.23B | Nov 10, 2022 |
| FY2021 | Sep 30, 2020 | $22.36B | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $19.14B | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $14.01B | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $12.93B | Nov 9, 2018 |
| FY2017 | Sep 30, 2016 | $11.38B | Nov 13, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($9.69B) | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | ($6.29B) | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | ($1.98B) | Nov 7, 2024 |
| FY2023 | Sep 30, 2022 | ($3.77B) | Nov 9, 2023 |
| FY2022 | Sep 30, 2021 | ($2.92B) | Nov 10, 2022 |
| FY2021 | Sep 30, 2020 | ($3.97B) | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | ($2.89B) | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | ($1.81B) | Nov 19, 2019 |
| FY2020 | Sep 30, 2017 | ($2.95B) | Nov 12, 2020 |
| FY2019 | Sep 30, 2016 | ($651.49M) | Nov 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.61B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $10.42B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $8.99B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $8.64B | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | $8.57B | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | $7.89B | Nov 10, 2022 |
| FY2021 | Sep 30, 2019 | $7.82B | Nov 16, 2021 |
| FY2020 | Sep 30, 2018 | $6.22B | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | $5.75B | Nov 19, 2019 |
| FY2018 | Sep 30, 2016 | $5.68B | Nov 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($10.61B) | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | ($7.36B) | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | ($2.62B) | Nov 7, 2024 |
| FY2023 | Sep 30, 2022 | ($3.91B) | Nov 9, 2023 |
| FY2022 | Sep 30, 2021 | ($3.71B) | Nov 10, 2022 |
| FY2021 | Sep 30, 2020 | ($4.36B) | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | ($3.12B) | Nov 12, 2020 |
| FY2019 | Oct 1, 2018 | ($2.24B) | Nov 19, 2019 |
| FY2019 | Sep 30, 2018 | ($2.25B) | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | ($3.19B) | Nov 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.81B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $6.26B | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | $3.47B | Nov 7, 2024 |
| FY2023 | Sep 30, 2022 | $3.00B | Nov 9, 2023 |
| FY2022 | Sep 30, 2021 | $4.79B | Nov 10, 2022 |
| FY2021 | Sep 30, 2020 | $4.72B | Nov 16, 2021 |
| FY2021 | Sep 30, 2019 | $1.47B | Nov 16, 2021 |
| FY2021 | Sep 30, 2018 | $2.07B | Nov 16, 2021 |
| FY2019 | Sep 30, 2017 | $650.56M | Nov 19, 2019 |
| FY2019 | Sep 30, 2016 | $1.59B | Nov 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $29.29B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $24.39B | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | $19.40B | Nov 7, 2024 |
| FY2023 | Sep 30, 2022 | $19.45B | Nov 9, 2023 |
| FY2022 | Sep 30, 2021 | $19.65B | Nov 10, 2022 |
| FY2021 | Sep 30, 2020 | $19.66B | Nov 16, 2021 |
| FY2020 | Sep 30, 2019 | $16.55B | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $12.58B | Nov 19, 2019 |
| FY2018 | Sep 30, 2017 | $11.46B | Nov 9, 2018 |
| FY2017 | Sep 30, 2016 | $10.00B | Nov 13, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 32 | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | 25 | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | 22 | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | 13 | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | 10 | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | 8 | Nov 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 32 | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | 25 | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | 22 | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | 13 | Nov 7, 2024 |
| FY2023 | Sep 30, 2021 | 10 | Nov 9, 2023 |
| FY2022 | Sep 30, 2020 | 8 | Nov 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Sep 30, 2012 | 52.16M | Nov 16, 2012 |
| FY2011 | Sep 30, 2011 | 50.83M | Nov 18, 2011 |
| FY2011 | Sep 30, 2010 | 49.93M | Nov 18, 2011 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $159.00M | Nov 12, 2025 |